PML and acute promyelocytic leukemia: Yet, mutations in PML arsenic binding site in Box B2 (discovered in therapy-resistant APL patients) alter basal NB assembly and blunt ATO response (Jeanne et al., 2010; Lehmann-Che et al., 2014; Liu et al., 2016; Zhu et al., 2014).